Silence Therapeutics Begins Phase I Trial of Cancer Rx, Posts Higher '08 Losses

Preparations for the clinical study — the company's first — contributed to a 40 percent rise in research and development spending in 2008, which drove a 45 percent increase in net losses.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories